Latest News for: n01

Edit

JOYEE N01 Rolls Off Global Production Line as First Batch Delivery Ceremony for 2,000 Overseas ...

The Daily Times 16 Nov 2026
YANCHENG, China, Nov. 15, 2026 /PRNewswire/ -- On October 28, the ceremony for the global mass production launch of the JOYEE N01 and the first batch delivery of 2,000 overseas orders was grandly held at the Yancheng Branch of FAW ... .
Edit

JOYEE N01 sale de la línea de producción global y se celebra la ceremonia de ...

Morgan Citizen 15 Nov 2026
YANCHENG, China, 15 de noviembre de 2026 /PRNewswire/ -- El 28 de octubre, la ceremonia de arranque de la producción en masa global del JOYEE N01 y de la primera entrega de 2.000 pedidos en el extranjero se celebró con ... .
Edit

JOYEE N01 Rolls Off Global Production Line as First Batch Delivery Ceremony for 2,000 Overseas Orders Takes Place

PR Newswire 15 Nov 2026
15, 2026 /PRNewswire/ -- On October 28, the ceremony for the global mass production launch of the JOYEE N01 and the first batch delivery of 2,000 overseas orders was grandly held at the Yancheng Branch of FAW.
Edit

JOYEE N01 Global Mass Production Launch and First Batch Delivery of 2,000 Overseas Orders Kicks Off

PR Newswire 07 Nov 2026
7, 2026 /PRNewswire/ -- On October 28, the ceremony for the global mass production launch of the JOYEE N01 and the first batch delivery of 2,000 overseas orders was grandly held at the Yancheng Branch of China FAW.
Edit

FAW Bestune starts overseas deliveries of JOYEE N01

China Daily 06 Nov 2026
FAW Bestune has started overseas deliveries of its JOYEE N01 electric vehicle, handing over the first 500 units to African customers as part of an initial overseas order for 2,000 vehicles.
Edit

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in ...

Morgan Citizen 09 Oct 2026
SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) ... .
Edit

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

PR Newswire 09 Oct 2026
... (Teprotumumab N01 Injection, R&D code ... SYCUME® (teprotumumab N01) is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody developed by Innovent for the treatment of TED.
  • 1
×